Cargando…
Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy
PURPOSE: Heparanase cleaves heparan sulfate side chains of heparan sulfate proteoglycans, activity that is implicated in angiogenesis. Proteolytic cleavage of proheparanase by cathepsin L leads to the formation of catalytically active heparanase. We investigated the expression levels of heparanase e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851855/ https://www.ncbi.nlm.nih.gov/pubmed/27168718 |
_version_ | 1782429872080027648 |
---|---|
author | Abu El-Asrar, Ahmed M. Siddiquei, Mohammad Mairaj Nawaz, Mohd Imtiaz De Hertogh, Gert Mohammad, Ghulam Alam, Kaiser Mousa, Ahmed Opdenakker, Ghislain |
author_facet | Abu El-Asrar, Ahmed M. Siddiquei, Mohammad Mairaj Nawaz, Mohd Imtiaz De Hertogh, Gert Mohammad, Ghulam Alam, Kaiser Mousa, Ahmed Opdenakker, Ghislain |
author_sort | Abu El-Asrar, Ahmed M. |
collection | PubMed |
description | PURPOSE: Heparanase cleaves heparan sulfate side chains of heparan sulfate proteoglycans, activity that is implicated in angiogenesis. Proteolytic cleavage of proheparanase by cathepsin L leads to the formation of catalytically active heparanase. We investigated the expression levels of heparanase enzymatic activity and correlated these with the levels of cathepsin L, the angiogenic factors tissue factor (TF) and matrix metalloproteinase-9 (MMP-9), and the angiostatic factor tissue factor pathway inhibitor (TFPI) in proliferative diabetic retinopathy (PDR). METHODS: Vitreous samples from 25 patients with PDR and 20 nondiabetic patients and epiretinal membranes from 12 patients with PDR were studied with enzyme-linked immunosorbent assay, western blot analysis, and immunohistochemistry. RESULTS: We observed a significant increase in the expression of heparanase activity in vitreous samples from patients with PDR compared to the nondiabetic controls (p=0.027). Significant positive correlations were found between the levels of heparanase activity and the levels of cathepsin L (r=0.51; p=0.001), TF (r=0.6; p<0.0001), and TFPI (r=0.49; p=0.001). The expression levels of cathepsin L (p=0.019), TF (p<0.0001), TFPI (p<0.0001), and MMP-9 (p=0.029) were significantly higher in the vitreous samples with detected heparanase activity compared to the vitreous samples with undetected heparanase activity. Western blot analysis demonstrated proteolytic cleavage of TFPI in the vitreous samples from patients with PDR. In the epiretinal membranes, cathepsin L, TF, and TFPI were expressed in vascular endothelial cells and CD45-expressing leukocytes. Significant positive correlations were detected between the number of blood vessels that expressed CD31 and the number of blood vessels that expressed TF (r=0.9; p<0.0001) and TFPI (r=0.81; p=0.001). CONCLUSIONS: The coexpression of these angiogenesis regulatory factors suggests cross-talk between these factors and pathogenesis of PDR angiogenesis. |
format | Online Article Text |
id | pubmed-4851855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Molecular Vision |
record_format | MEDLINE/PubMed |
spelling | pubmed-48518552016-05-10 Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy Abu El-Asrar, Ahmed M. Siddiquei, Mohammad Mairaj Nawaz, Mohd Imtiaz De Hertogh, Gert Mohammad, Ghulam Alam, Kaiser Mousa, Ahmed Opdenakker, Ghislain Mol Vis Research Article PURPOSE: Heparanase cleaves heparan sulfate side chains of heparan sulfate proteoglycans, activity that is implicated in angiogenesis. Proteolytic cleavage of proheparanase by cathepsin L leads to the formation of catalytically active heparanase. We investigated the expression levels of heparanase enzymatic activity and correlated these with the levels of cathepsin L, the angiogenic factors tissue factor (TF) and matrix metalloproteinase-9 (MMP-9), and the angiostatic factor tissue factor pathway inhibitor (TFPI) in proliferative diabetic retinopathy (PDR). METHODS: Vitreous samples from 25 patients with PDR and 20 nondiabetic patients and epiretinal membranes from 12 patients with PDR were studied with enzyme-linked immunosorbent assay, western blot analysis, and immunohistochemistry. RESULTS: We observed a significant increase in the expression of heparanase activity in vitreous samples from patients with PDR compared to the nondiabetic controls (p=0.027). Significant positive correlations were found between the levels of heparanase activity and the levels of cathepsin L (r=0.51; p=0.001), TF (r=0.6; p<0.0001), and TFPI (r=0.49; p=0.001). The expression levels of cathepsin L (p=0.019), TF (p<0.0001), TFPI (p<0.0001), and MMP-9 (p=0.029) were significantly higher in the vitreous samples with detected heparanase activity compared to the vitreous samples with undetected heparanase activity. Western blot analysis demonstrated proteolytic cleavage of TFPI in the vitreous samples from patients with PDR. In the epiretinal membranes, cathepsin L, TF, and TFPI were expressed in vascular endothelial cells and CD45-expressing leukocytes. Significant positive correlations were detected between the number of blood vessels that expressed CD31 and the number of blood vessels that expressed TF (r=0.9; p<0.0001) and TFPI (r=0.81; p=0.001). CONCLUSIONS: The coexpression of these angiogenesis regulatory factors suggests cross-talk between these factors and pathogenesis of PDR angiogenesis. Molecular Vision 2016-04-30 /pmc/articles/PMC4851855/ /pubmed/27168718 Text en Copyright © 2016 Molecular Vision. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed. |
spellingShingle | Research Article Abu El-Asrar, Ahmed M. Siddiquei, Mohammad Mairaj Nawaz, Mohd Imtiaz De Hertogh, Gert Mohammad, Ghulam Alam, Kaiser Mousa, Ahmed Opdenakker, Ghislain Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title_full | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title_fullStr | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title_full_unstemmed | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title_short | Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy |
title_sort | coexpression of heparanase activity, cathepsin l, tissue factor, tissue factor pathway inhibitor, and mmp-9 in proliferative diabetic retinopathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851855/ https://www.ncbi.nlm.nih.gov/pubmed/27168718 |
work_keys_str_mv | AT abuelasrarahmedm coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT siddiqueimohammadmairaj coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT nawazmohdimtiaz coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT dehertoghgert coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT mohammadghulam coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT alamkaiser coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT mousaahmed coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy AT opdenakkerghislain coexpressionofheparanaseactivitycathepsinltissuefactortissuefactorpathwayinhibitorandmmp9inproliferativediabeticretinopathy |